Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 7, 2023.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
In episode 86 of the Mind Moments Podcast, Dilesh Doshi, PharmD, vice president of Health Economics and Outcomes Research at Acadia Pharmaceuticals, spoke on the advantages and benefits of pimavanserin (Nuplazid; Acadia), the only FDA-approved therapy to treat Parkinson disease psychosis.
In episode 6 of this Peer Exchange series on "Updates in the Management of Neuromyelitis Optica Spectrum Disorder Care (NMOSD)", experts in neurology discuss the current neuromyelitis optica spectrum disorder treatment landscape.
In the latest edition of our in-depth Q&A series, the immunology fellow at Brigham and Women’s Hospital discussed the current understanding of the disease and the needed efforts to raise awareness. She spoke specifically about hot topics in MOGAD-related research, the potential for a first FDA-approved therapy, and how the clinical community learns from diseases like MS and NMOSD.
To recap the recent 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19-22, in Dallas, Texas, NeurologyLive® compiled a number of interviews with experts from the conference to offer an overview of the state of care and discussions on the hottest topics in neuromuscular diseases.
The neuro-ophthalmologist at Mayo Clinic sat down to discuss the importance of raising awareness for NMOSD, described the clinical lessons learned since the introduction of therapies to treat NMOSD, as well as the next steps in the management of the disease and the discussions around tackling neurodegeneration and remyelination. [WATCH TIME: 3 minutes]